Abbott Laboratories (ABT)

·                  Abbott is conducting innovative research in neuroscience, where we have developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as Alzheimer’s disease and schizophrenia. Abbott recently advanced two compounds into Phase II development for Alzheimer’s disease.

·                  Abbott is also pursuing compounds that could provide relief across a broad spectrum of pain states, such as osteoarthritis, postoperative pain and cancer pain. We recently expanded our early-stage pain portfolio with the addition of an anti-nerve growth factor (NGF) biologic for chronic pain.

·                 

·                  Abbott is conducting innovative research in neuroscience, where we have developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia.

·                  Abbott is also pursuing compounds that could provide relief across a broad spectrum of pain states, such as osteoarthritis, postoperative pain and cancer pain.

·                 

·                  Abbott is conducting innovative research in neuroscience, where we have developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia.

·                  We’re also pursuing compounds that could provide relief across a broad spectrum of pain states, such as osteoarthritis, postoperative pain and cancer pain.

·                 

·                  Abbott is conducting innovative research in neuroscience, where we have developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia.

·                 

·                  Abbott is conducting innovative research in neuroscience, where we’ve developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia. Abbott is also working to advance compounds that have the potential to meet the market need for a non-opioid pain therapy. Our work in neuroscience is focused on several promising investigational platforms including NNRs, H3, Calpain and TRPV1, among others.

·                 

             Abbott is conducting innovative research in neuroscience, where we’ve developed compounds that target receptors in the brain that help regulate pain, mood, memory and other neurological functions to address conditions, such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia. Our work in neuroscience is focused on several promising investigational platforms including NNRs, H3, Calpain and TRPV1, among others.

             Abbott is also working to advance compounds that have the potential to meet the market need for a non-opioid pain therapy.

·               

·                  Abbott is conducting innovative research in neuroscience, where we’ve developed compounds that target receptors in the brain that help regulate pain, mood, memory and other neurological functions to address conditions such as attention deficit hyperactivity disorder, Alzheimer’s disease and schizophrenia. We have a number of novel early-and-mid-stage compounds that have the potential to address critical, unmet needs for patients with these conditions.

·                  Abbott is also working to advance compounds that have the potential to meet the market need for a non-opioid pain therapy.

·                 

·                  Abbott’s neuroscience pipeline includes several unique approaches for treating a number of diseases including schizophrenia, ADHD, Alzheimer’s disease and pain. Compounds under development target neuronal nicotinic receptors (NNRs), which play a role in regulating pain, memory and other neurological functions.

·                 

o        Abbott’s neuroscience pipeline includes several unique approaches for treating a number of diseases including schizophrenia, ADHD, Alzheimer’s disease and pain. Compounds under development target neuronal nicotinic receptors (NNRs), which play a role in regulating pain, memory and other neurological functions.

·                 

·                  Abbott’s neuroscience pipeline includes several unique approaches for treating a number of diseases including schizophrenia, ADHD, Alzheimer’s disease and pain. Compounds under development include neuronal nicotinic receptor agonists (NNR’s) and dopamine 3 (D3) receptor antagonists, both of which play a role in regulating pain, memory and other neurological functions.

·                  Abbott’s neuroscience pipeline includes ABT-089 and ABT-894, two NNRs in Phase II, ABT-925, a D3 receptor antagonist in Phase II, and several compounds in earlier stage development.

·                 

o                 Abbott’s neuroscience pipeline includes several unique approaches for treating a number of diseases including schizophrenia, Alzheimer’s disease and pain. Compounds under development include neuronal nicotinic receptor antagonists and D3 receptor antagonists, which play a role in regulating pain, memory and other neurological functions.

·